G
Georg Schett
Researcher at University of Erlangen-Nuremberg
Publications - 1110
Citations - 65568
Georg Schett is an academic researcher from University of Erlangen-Nuremberg. The author has contributed to research in topics: Medicine & Arthritis. The author has an hindex of 114, co-authored 938 publications receiving 52530 citations. Previous affiliations of Georg Schett include Institute of Molecular Biotechnology & University of Vienna.
Papers
More filters
Journal ArticleDOI
The pathogenesis of rheumatoid arthritis.
Iain B. McInnes,Georg Schett +1 more
TL;DR: The increased understanding of the immune mechanisms of rheumatoid arthritis has led to the development of a considerable number of new therapeutic agents that alter the natural history of the disease and reduce mortality.
Journal ArticleDOI
Cytokines in the pathogenesis of rheumatoid arthritis
Iain B. McInnes,Georg Schett +1 more
TL;DR: The crucial effector function of cytokines in the immunological processes that are central to the pathogenesis of rheumatoid arthritis are discussed.
Journal ArticleDOI
Dickkopf-1 is a master regulator of joint remodeling
Danielle Diarra,Marina Stolina,Karin Polzer,Jochen Zwerina,Michael S. Ominsky,Denise Dwyer,Adelheid Korb,Josef S Smolen,Markus H. Hoffmann,Clemens Scheinecker,Desiree van der Heide,Robert Landewé,Dave Lacey,William G. Richards,Georg Schett,Georg Schett +15 more
TL;DR: By inhibiting Dickkopf-1 (DKK-1), a regulatory molecule of the Wnt pathway, this work was able to reverse theBone-destructive pattern of a mouse model of rheumatoid arthritis to the bone-forming pattern of osteoarthritis, suggesting that the WNT pathway is a key regulator of joint remodeling.
Journal ArticleDOI
Trial of Tocilizumab in Giant-Cell Arteritis.
John H. Stone,Katie Tuckwell,Sophie Dimonaco,Micki Klearman,Martin Aringer,Daniel Engelbert Blockmans,Elisabeth Brouwer,Maria C. Cid,Bhaskar Dasgupta,Juergen Rech,Carlo Salvarani,Georg Schett,Hendrik Schulze-Koops,Robert Spiera,Sebastian Unizony,Neil Collinson +15 more
TL;DR: Tocilizumab, received weekly or every other week, combined with a 26‐week prednisone taper was superior to either 26‐ week or 52‐weekprednisone tapering plus placebo with regard to sustained glucocorticoid‐free remission in patients with giant‐cell arteritis.
Journal ArticleDOI
Pathogenetic insights from the treatment of rheumatoid arthritis.
Iain B. McInnes,Georg Schett +1 more
TL;DR: It becomes apparent that understanding the effects of specific immune interventions can elucidate definitive molecular or cellular nodes that are essential to maintain complex inflammatory networks that subserve diseases like rheumatoid arthritis.